idebenone + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia
Conditions
Friedreich's Ataxia
Trial Timeline
Apr 1, 2006 โ Jan 1, 2010
NCT ID
NCT00905268About idebenone + Placebo
idebenone + Placebo is a phase 3 stage product being developed by Santhera Pharmaceuticals for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT00905268. Target conditions include Friedreich's Ataxia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01495715 | Phase 3 | Withdrawn |
| NCT01303406 | Phase 3 | Completed |
| NCT00747487 | Phase 2 | Completed |
| NCT00905268 | Phase 3 | Completed |
| NCT00654784 | Phase 2 | Completed |
Competing Products
11 competing products in Friedreich's Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Interferon ฮณ-1b | Amgen | Phase 3 | 76 |
| interferon ฮณ-1b | Amgen | Phase 3 | 76 |
| Interferon ฮณ-1b + Placebo | Amgen | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2/3 | 64 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 49 |
| Omeveloxolone | Biogen | Pre-clinical | 20 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 49 |
| SGT-212 | Solid Biosciences | Phase 1 | 25 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |